Par Pharm Company Profile

✉ Email this page to a colleague

PAR PHARM has one hundred and fifty-three approved drugs.

There is one US patent protecting PAR PHARM drugs. There are thirteen tentative approvals on PAR PHARM drugs.

There are nine patent family members on PAR PHARM drugs in eight countries and one hundred and ninety supplementary protection certificates in fifteen countries.

International Patents:	9
US Patents:	1
Tradenames:	98
Ingredients:	96
NDAs:	153
Patent Litigation for Par Pharm:	See patent lawsuits for Par Pharm
PTAB Cases with Par Pharm as petitioner:	See PTAB cases with Par Pharm as petitioner

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Par Pharm Inc	TIZANIDINE HYDROCHLORIDE	tizanidine hydrochloride	TABLET;ORAL	207170-001	Jan 26, 2017		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Par Pharm	CALCITONIN-SALMON	calcitonin salmon	SPRAY, METERED;NASAL	076979-001	Jun 8, 2009		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Par Pharm Inc	DEXMETHYLPHENIDATE HYDROCHLORIDE	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	202842-005	Nov 30, 2016	AB	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Par Pharm Inc	OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE	amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	206137-001	Oct 26, 2016	AB	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Par Pharm Inc	COLCHICINE	colchicine	CAPSULE;ORAL	208678-001	Nov 29, 2018	AB	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Par Pharm	NASCOBAL	cyanocobalamin	GEL, METERED;NASAL	019722-001	Nov 5, 1996	4,724,231	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Nasal Spray	500 mcg/spray	➤ Subscribe	2017-04-28

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
European Patent Office	1948613	⤷ Try a Trial
China	101163679	⤷ Try a Trial
World Intellectual Property Organization (WIPO)	2006115626	⤷ Try a Trial
Japan	2008538560	⤷ Try a Trial
Japan	5378788	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0450097	SPC/GB09/037	United Kingdom	⤷ Try a Trial	PRODUCT NAME: TOLVAPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/09/539/001 20090803; UK EU/1/09/539/002 20090803; UK EU/1/09/539/003 20090803; UK EU/1/09/539/004 20090803
0443983	2007C/043	Belgium	⤷ Try a Trial	PRODUCT NAME: AMLODIPINE ET VALSARTAN; NATL. REGISTRATION NO/DATE: EU/1/06/370/001 20070118; FIRST REGISTRATION: CH 57771 20061222
0237929	97C0112	Belgium	⤷ Try a Trial	PRODUCT NAME: TOLCAPONE; REGISTRATION NO/DATE: EU/1/97/044/001 19970827
1856135	CR 2020 00018	Denmark	⤷ Try a Trial	PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113
1915993	300625	Netherlands	⤷ Try a Trial	PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.